Skip to main content
Top
Published in: Journal of Nephrology 4/2017

01-08-2017 | Review

Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans

Authors: Riccardo Magistroni, Alessandra Boletta

Published in: Journal of Nephrology | Issue 4/2017

Login to get access

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease characterized by bilateral renal cyst formation. ADPKD is one of the most common rare disorders, accounting for ~10% of all patients with end-stage renal disease (ESRD). ADPKD is a chronic disorder in which the gradual expansion of cysts that form in a minority of nephrons eventually causes loss of renal function due to the compression and degeneration of the surrounding normal parenchyma. Numerous deranged pathways have been identified in the cyst-lining epithelia, prompting the design of potential therapies. Several of these potential treatments have proved effective in slowing down disease progression in pre-clinical animal studies, while only one has subsequently been proven to effectively slow down disease progression in patients, and it has recently been approved for therapy in Europe, Canada and Japan. Among the affected cellular functions and pathways, recent investigations have described metabolic derangement in ADPKD as a major trait offering additional opportunities for targeted therapies. In particular, increased aerobic glycolysis (the Warburg effect) has been described as a prominent feature of ADPKD kidneys and its inhibition using the glucose analogue 2-deoxy-d-glucose (2DG) proved effective in slowing down disease progression in preclinical models of the disease. At the same time, previous clinical experiences have been reported with 2DG, showing that this compound is well tolerated in humans with minimal and reversible side effects. In this work, we review the literature and speculate that 2DG could be a good candidate for a clinical trial in humans affected by ADPKD.
Literature
1.
go back to reference Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Areste N, de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT, Registry E-E, Euro CC, Wgikd (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29(Suppl 4):iv15–i25. doi:10.1093/ndt/gfu017 CrossRefPubMed Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Areste N, de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT, Registry E-E, Euro CC, Wgikd (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29(Suppl 4):iv15–i25. doi:10.​1093/​ndt/​gfu017 CrossRefPubMed
2.
go back to reference Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS (2016) Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. doi:10.1093/ndt/gfw240 PubMed Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS (2016) Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. doi:10.​1093/​ndt/​gfw240 PubMed
5.
go back to reference Peters DJ, Sandkuijl LA (1992) Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 97:128–139CrossRefPubMed Peters DJ, Sandkuijl LA (1992) Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 97:128–139CrossRefPubMed
6.
go back to reference Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Ferec C, Le Meur Y (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24(6):1006–1013. doi:10.1681/ASN.2012070650 CrossRefPubMedPubMedCentral Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Ferec C, Le Meur Y (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24(6):1006–1013. doi:10.​1681/​ASN.​2012070650 CrossRefPubMedPubMedCentral
7.
go back to reference Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9):820–829 pii]10.1056/NEJMoa0907419CrossRefPubMed Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9):820–829 pii]10.1056/NEJMoa0907419CrossRefPubMed
8.
go back to reference Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9):830–840. doi:10.1056/NEJMoa1003491 CrossRefPubMed Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9):830–840. doi:10.​1056/​NEJMoa1003491 CrossRefPubMed
10.
go back to reference Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. doi:10.1056/NEJMoa1205511 Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. doi:10.​1056/​NEJMoa1205511
14.
go back to reference Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19(4):488–493. doi:10.1038/nm.3092 CrossRefPubMedPubMedCentral Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19(4):488–493. doi:10.​1038/​nm.​3092 CrossRefPubMedPubMedCentral
17.
go back to reference Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH (2015) The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol 309 (6):F492-498. doi:10.1152/ajprenal.00238.2015 PubMedCentral Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH (2015) The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol 309 (6):F492-498. doi:10.​1152/​ajprenal.​00238.​2015 PubMedCentral
18.
go back to reference Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V, Gurgone A, Antunes S, D’Adamo P, Esposito A, Musco G, Boletta A (2015) 2-Deoxy-d-glucose ameliorates PKD progression. J Am Soc Nephrol. doi:10.1681/ASN.2015030231 Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V, Gurgone A, Antunes S, D’Adamo P, Esposito A, Musco G, Boletta A (2015) 2-Deoxy-d-glucose ameliorates PKD progression. J Am Soc Nephrol. doi:10.​1681/​ASN.​2015030231
19.
go back to reference Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X (2015) Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest 125(6):2399–2412. doi:10.1172/JCI80467 CrossRefPubMedPubMedCentral Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X (2015) Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest 125(6):2399–2412. doi:10.​1172/​JCI80467 CrossRefPubMedPubMedCentral
20.
go back to reference Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437–1447. doi:10.1681/ASN.2015020132 CrossRefPubMed Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437–1447. doi:10.​1681/​ASN.​2015020132 CrossRefPubMed
23.
go back to reference Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, Kessler L, Moulin B (2011) Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 91(7):757–764. doi:10.1097/TP.0b013e31820f0877 PubMed Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, Kessler L, Moulin B (2011) Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 91(7):757–764. doi:10.​1097/​TP.​0b013e31820f0877​ PubMed
24.
go back to reference Gentil MA, Luna E, Rodriguez-Algarra G, Osuna A, Gonzalez-Molina M, Mazuecos A, Cubero JJ, Del Castillo D (2002) Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C. Nephrol Dial Transplant 17(5):887–891CrossRefPubMed Gentil MA, Luna E, Rodriguez-Algarra G, Osuna A, Gonzalez-Molina M, Mazuecos A, Cubero JJ, Del Castillo D (2002) Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C. Nephrol Dial Transplant 17(5):887–891CrossRefPubMed
26.
go back to reference Prakash J, Rathore SS, Brojen Singh T, Choudhury TA, Prabhakar, Usha (2012) New onset diabetes after transplantation (NODAT): analysis of pre-transplant risk factors in renal allograft recipients. Indian J Transplant 6(3):77–82. doi:10.1016/j.ijt.2012.07.003 CrossRef Prakash J, Rathore SS, Brojen Singh T, Choudhury TA, Prabhakar, Usha (2012) New onset diabetes after transplantation (NODAT): analysis of pre-transplant risk factors in renal allograft recipients. Indian J Transplant 6(3):77–82. doi:10.​1016/​j.​ijt.​2012.​07.​003 CrossRef
27.
go back to reference Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM (1999) Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 14(5):1244–1246CrossRefPubMed Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM (1999) Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 14(5):1244–1246CrossRefPubMed
29.
go back to reference Razeghi E, Heydarian P, Amerian M, Pourmand G (2010) The risk factors for diabetes mellitus after kidney transplantation. Saudi J Kidney Dis Transpl 21(6):1038–1043PubMed Razeghi E, Heydarian P, Amerian M, Pourmand G (2010) The risk factors for diabetes mellitus after kidney transplantation. Saudi J Kidney Dis Transpl 21(6):1038–1043PubMed
30.
go back to reference Pietrzak-Nowacka M, Safranow K, Rozanski J, Debska-Slizien A, Domanski L, Dziewanowski K, Glyda M, Jankowska M, Nocen M, Pabisiak K, Rutkowski B, Wisniewska M, Ciechanowski K (2008) Autosomal dominant polycystic kidney disease is not a risk factor for post-transplant diabetes mellitus. Matched-pair design multicenter study. Arch Med Res 39(3):312–319. doi:10.1016/j.arcmed.2007.10.003 CrossRefPubMed Pietrzak-Nowacka M, Safranow K, Rozanski J, Debska-Slizien A, Domanski L, Dziewanowski K, Glyda M, Jankowska M, Nocen M, Pabisiak K, Rutkowski B, Wisniewska M, Ciechanowski K (2008) Autosomal dominant polycystic kidney disease is not a risk factor for post-transplant diabetes mellitus. Matched-pair design multicenter study. Arch Med Res 39(3):312–319. doi:10.​1016/​j.​arcmed.​2007.​10.​003 CrossRefPubMed
31.
go back to reference Courivaud C, Ladriere M, Toupance O, Caillard S, Hurault de Ligny B, Ryckelynck JP, Moulin B, Rieu P, Frimat L, Chalopin JM, Chauve S, Kazory A, Ducloux D (2011) Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. Clin Transplant 25(5):794–799. doi:10.1111/j.1399-0012.2010.01367.x CrossRefPubMed Courivaud C, Ladriere M, Toupance O, Caillard S, Hurault de Ligny B, Ryckelynck JP, Moulin B, Rieu P, Frimat L, Chalopin JM, Chauve S, Kazory A, Ducloux D (2011) Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. Clin Transplant 25(5):794–799. doi:10.​1111/​j.​1399-0012.​2010.​01367.​x CrossRefPubMed
32.
go back to reference Hjelmesaeth J, Hartmann A (1999) Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 14(10):2521–2522CrossRefPubMed Hjelmesaeth J, Hartmann A (1999) Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 14(10):2521–2522CrossRefPubMed
33.
go back to reference Ruderman I, Masterson R, Yates C, Gorelik A, Cohney SJ, Walker RG (2012) New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study. Nephrology (Carlton) 17 (1):89–96. doi:10.1111/j.1440-1797.2011.01507.x CrossRef Ruderman I, Masterson R, Yates C, Gorelik A, Cohney SJ, Walker RG (2012) New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study. Nephrology (Carlton) 17 (1):89–96. doi:10.​1111/​j.​1440-1797.​2011.​01507.​x CrossRef
34.
go back to reference Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D (2012) New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 35(1):181–188. doi:10.2337/dc11-1230 CrossRefPubMed Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D (2012) New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 35(1):181–188. doi:10.​2337/​dc11-1230 CrossRefPubMed
35.
go back to reference Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, Kreis H, Legendre C, Mamzer-Bruneel MF (2011) Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int 24(6):582–587. doi:10.1111/j.1432-2277.2011.01237.x CrossRefPubMed Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, Kreis H, Legendre C, Mamzer-Bruneel MF (2011) Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int 24(6):582–587. doi:10.​1111/​j.​1432-2277.​2011.​01237.​x CrossRefPubMed
36.
go back to reference Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, Anthanont P, Erickson SB (2016) The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis. Can J Diabetes. doi:10.1016/j.jcjd.2016.03.001 PubMed Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, Anthanont P, Erickson SB (2016) The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis. Can J Diabetes. doi:10.​1016/​j.​jcjd.​2016.​03.​001 PubMed
37.
go back to reference Pietrzak-Nowacka M, Safranow K, Byra E, Nowosiad M, Marchelek-Mysliwiec M, Ciechanowski K (2010) Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest 70(8):561–567. doi:10.3109/00365513.2010.527012 CrossRefPubMed Pietrzak-Nowacka M, Safranow K, Byra E, Nowosiad M, Marchelek-Mysliwiec M, Ciechanowski K (2010) Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest 70(8):561–567. doi:10.​3109/​00365513.​2010.​527012 CrossRefPubMed
39.
go back to reference Vareesangthip K, Tong P, Wilkinson R, Thomas TH (1997) Insulin resistance in adult polycystic kidney disease. Kidney Int 52(2):503–508CrossRefPubMed Vareesangthip K, Tong P, Wilkinson R, Thomas TH (1997) Insulin resistance in adult polycystic kidney disease. Kidney Int 52(2):503–508CrossRefPubMed
40.
go back to reference Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW (2012) The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27(7):2862–2865. doi:10.1093/ndt/gfr744 CrossRefPubMed Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW (2012) The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27(7):2862–2865. doi:10.​1093/​ndt/​gfr744 CrossRefPubMed
41.
45.
go back to reference Minor RK, Smith DL Jr, Sossong AM, Kaushik S, Poosala S, Spangler EL, Roth GS, Lane M, Allison DB, de Cabo R, Ingram DK, Mattison JA (2010) Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol 243(3):332–339. doi:10.1016/j.taap.2009.11.025 CrossRefPubMed Minor RK, Smith DL Jr, Sossong AM, Kaushik S, Poosala S, Spangler EL, Roth GS, Lane M, Allison DB, de Cabo R, Ingram DK, Mattison JA (2010) Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol 243(3):332–339. doi:10.​1016/​j.​taap.​2009.​11.​025 CrossRefPubMed
47.
go back to reference Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013) A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71(2):523–530. doi:10.1007/s00280-012-2045-1 CrossRefPubMed Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013) A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71(2):523–530. doi:10.​1007/​s00280-012-2045-1 CrossRefPubMed
48.
go back to reference Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388–1394. doi:10.1002/pros.21172 CrossRefPubMedPubMedCentral Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388–1394. doi:10.​1002/​pros.​21172 CrossRefPubMedPubMedCentral
49.
go back to reference Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V (2005) Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181(8):507–514. doi:10.1007/s00066-005-1320-z CrossRefPubMed Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V (2005) Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181(8):507–514. doi:10.​1007/​s00066-005-1320-z CrossRefPubMed
50.
go back to reference Landau BR, Laszlo J, Stengle J, Burk D (1958) Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-d-glucose. J Natl Cancer Inst 21(3):485–494PubMed Landau BR, Laszlo J, Stengle J, Burk D (1958) Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-d-glucose. J Natl Cancer Inst 21(3):485–494PubMed
51.
go back to reference Kilbourne ED (1959) Inhibition of influenza virus multiplication with a glucose antimetabolite (2-deoxy-d-glucose). Nature 183(4656):271–272CrossRefPubMed Kilbourne ED (1959) Inhibition of influenza virus multiplication with a glucose antimetabolite (2-deoxy-d-glucose). Nature 183(4656):271–272CrossRefPubMed
52.
go back to reference Courtney RJ, Steiner SM, Benyesh-Melnick M (1973) Effects of 2-deoxy-d-glucose on herpes simplex virus replication. Virology 52(2):447–455CrossRefPubMed Courtney RJ, Steiner SM, Benyesh-Melnick M (1973) Effects of 2-deoxy-d-glucose on herpes simplex virus replication. Virology 52(2):447–455CrossRefPubMed
53.
go back to reference Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA (2012) Activation of the unfolded protein response by 2-deoxy-d-glucose inhibits Kaposi’s sarcoma-associated herpesvirus replication and gene expression. Antimicrob Agents Chemother 56(11):5794–5803. doi:10.1128/AAC.01126-12 CrossRefPubMedPubMedCentral Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA (2012) Activation of the unfolded protein response by 2-deoxy-d-glucose inhibits Kaposi’s sarcoma-associated herpesvirus replication and gene expression. Antimicrob Agents Chemother 56(11):5794–5803. doi:10.​1128/​AAC.​01126-12 CrossRefPubMedPubMedCentral
56.
57.
go back to reference Che Q, Lin L, Ai Q, Ge P, Dai J, Jiang R, Zhou D, Wan J, Zhang L (2015) Caloric restriction mimetic 2-deoxyglucose alleviated lethal liver injury induced by lipopolysaccharide/d-galactosamine in mice. Biochem Biophys Res Commun 459(3):541–546. doi:10.1016/j.bbrc.2015.02.145 CrossRefPubMed Che Q, Lin L, Ai Q, Ge P, Dai J, Jiang R, Zhou D, Wan J, Zhang L (2015) Caloric restriction mimetic 2-deoxyglucose alleviated lethal liver injury induced by lipopolysaccharide/d-galactosamine in mice. Biochem Biophys Res Commun 459(3):541–546. doi:10.​1016/​j.​bbrc.​2015.​02.​145 CrossRefPubMed
58.
go back to reference Lee J, Bruce-Keller AJ, Kruman Y, Chan SL, Mattson MP (1999) 2-Deoxy-d-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. J Neurosci Res 57(1):48–61CrossRefPubMed Lee J, Bruce-Keller AJ, Kruman Y, Chan SL, Mattson MP (1999) 2-Deoxy-d-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. J Neurosci Res 57(1):48–61CrossRefPubMed
59.
go back to reference Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J Neurosci Res 57(2):195–206CrossRefPubMed Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J Neurosci Res 57(2):195–206CrossRefPubMed
63.
go back to reference Farooque A, Afrin F, Adhikari JS, Dwarakanath BS (2009) Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-d-glucose. J Cancer Res Ther 5(Suppl 1):S32–S35. doi:10.4103/0973-1482.55138 PubMed Farooque A, Afrin F, Adhikari JS, Dwarakanath BS (2009) Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-d-glucose. J Cancer Res Ther 5(Suppl 1):S32–S35. doi:10.​4103/​0973-1482.​55138 PubMed
64.
go back to reference Burckhardt D, Stalder GA (1975) Cardiac changes during 2-deoxy-d-glucose test. A study in patients with selective vagotomy and pyloroplasty. Digestion 12(1):1–8CrossRefPubMed Burckhardt D, Stalder GA (1975) Cardiac changes during 2-deoxy-d-glucose test. A study in patients with selective vagotomy and pyloroplasty. Digestion 12(1):1–8CrossRefPubMed
65.
go back to reference Stalder GA, Schultheiss HR, Allgower M (1972) Use of 2-deoxy-d-glucose for testing completeness of vagotomy in man. Gastroenterology 63(4):552–556PubMed Stalder GA, Schultheiss HR, Allgower M (1972) Use of 2-deoxy-d-glucose for testing completeness of vagotomy in man. Gastroenterology 63(4):552–556PubMed
Metadata
Title
Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans
Authors
Riccardo Magistroni
Alessandra Boletta
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 4/2017
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-017-0395-9

Other articles of this Issue 4/2017

Journal of Nephrology 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine